Pazopanib Vs. Local Therapy for Renal Cancer With Metastases
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The proposed study is a phase II randomized trial testing an innovative concept of comparing
local therapy to systemic therapy, e.g. pazopanib, in patients with newly diagnosed limited
metastatic RCC. We hypothesize that local therapy can prolong progression-free survival for
patients with limited metastasis, and delaying the initiation of systemic therapy does not
adversely affect survival. Patient will be stratified by Heng's criteria. Patients that are
curable by metastatectomy as well as patients with poor prognosis and high chance of disease
dissemination according to the prognostic factors will be excluded.